Literature DB >> 18692024

Sanguinarine cytotoxicity on mouse melanoma K1735-M2 cells--nuclear vs. mitochondrial effects.

Teresa L Serafim1, Júlio A C Matos, Vilma A Sardão, Gonçalo C Pereira, Ana F Branco, Sandro L Pereira, Donna Parke, Edward L Perkins, António J M Moreno, Jon Holy, Paulo J Oliveira.   

Abstract

Sanguinarine (SANG) is an alkaloid recognized to have anti-proliferative activity against various human tumour cell lines. No data is available on the susceptibility of advanced malignant melanoma to SANG, although this disease has a very poor prognosis if not detected in time due to the resistance to conventional chemotherapy. The present work was designed to study the nuclear and mitochondrial involvement in the pro-apoptotic effect of SANG in an invasive mouse melanoma cell line. The results obtained show that SANG is primarily accumulated by the cell nuclei, causing inhibition of cell proliferation and inducing cell death, as confirmed by an increase in sub-G1 peaks. At low concentrations, SANG induces mitochondrial depolarization in a sub-population of melanoma cells, which also generally displayed strong nuclear labelling of phosphorylated histone H2AX. Western blotting revealed an increase in p53, but not Bax protein, in both whole-cell extracts and in mitochondrial fractions. Isolated hepatic mitochondrial fractions revealed that SANG affects the mitochondrial respiratory chain, and has dual effects on mitochondrial calcium loading capacity. We suggest that SANG is able to induce apoptosis in metastatic melanoma cells. The knowledge of mitochondrial vs. nuclear effects of SANG is important in the development of this promising compound for clinical use against aggressive melanoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692024     DOI: 10.1016/j.bcp.2008.07.013

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Biophysical aspects and biological implications of the interaction of benzophenanthridine alkaloids with DNA.

Authors:  Motilal Maiti; Gopinatha Suresh Kumar
Journal:  Biophys Rev       Date:  2009-08-25

2.  GB7 acetate, a galbulimima alkaloid from Galbulimima belgraveana, possesses anticancer effects in colorectal cancer cells.

Authors:  Ziyin Li; Lianzhi Mao; Bin Yu; Huahuan Liu; Qiuyu Zhang; Zhongbo Bian; Xudong Zhang; Wenzhen Liao; Suxia Sun
Journal:  J Pharm Anal       Date:  2021-06-27

3.  Inhibitors of bacterial tubulin target bacterial membranes in vivo.

Authors:  Marie H Foss; Ye-Jin Eun; Charles I Grove; Daniel A Pauw; Nohemy A Sorto; Jarred W Rensvold; David J Pagliarini; Jared T Shaw; Douglas B Weibel
Journal:  Medchemcomm       Date:  2012-07-18       Impact factor: 3.597

4.  A mutant of SWAP-70, a phosphatidylinositoltrisphosphate binding protein, transforms mouse embryo fibroblasts, which is inhibited by sanguinarine.

Authors:  Yasuhisa Fukui; Sayoko Ihara
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

Review 5.  Antitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectives.

Authors:  Roberta Gaziano; Gabriella Moroni; Cristina Buè; Martino Tony Miele; Paola Sinibaldi-Vallebona; Francesca Pica
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

6.  Dissecting Drug-Induced Cytotoxicity and Metabolic Dysfunction in Conditionally Immortalized Human Proximal Tubule Cells.

Authors:  Charlotte A Hoogstraten; Jan A M Smeitink; Frans G M Russel; Tom J J Schirris
Journal:  Front Toxicol       Date:  2022-02-28

7.  Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling.

Authors:  Sabah Akhtar; Iman W Achkar; Kodappully S Siveen; Shilpa Kuttikrishnan; Kirti S Prabhu; Abdul Q Khan; Eiman I Ahmed; Fairooz Sahir; Jayakumar Jerobin; Afsheen Raza; Maysaloun Merhi; Hesham M Elsabah; Ruba Taha; Halima El Omri; Hatem Zayed; Said Dermime; Martin Steinhoff; Shahab Uddin
Journal:  Front Oncol       Date:  2019-04-17       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.